Clearmind Medicine Inc. Common Shares - CMND STOCK NEWS

Clearmind Medicine Inc. (Nasdaq: CMND) has partnered with JS First Sdn. Bhd to source global manufacturers and distributors for its MEAI-based alcohol substitute beverages. This strategic move follows Clearmind's recent entry into the non-alcoholic beverage market with its patented, neurologically active novel alcohol replacement drink. The beverage aims to offer the social benefits of alcohol without negative health impacts.

JS First will conduct research on manufacturing and licensing rights in foreign markets, identify manufacturing partners, and establish relationships with distributors globally. The collaboration targets markets in the U.S., Europe, Africa, and Southeast Asia. According to IWSR, the no- and low-alcohol market is valued at over $13 billion and is forecast to grow at a CAGR of +6% between 2023 and 2027.

Clearmind Medicine Inc. (Nasdaq: CMND) has received FDA approval for its Investigational New Drug (IND) application, allowing the company to proceed with a Phase I/IIa clinical trial in the United States for its proprietary MEAI-based CMND-100 oral capsule to treat alcohol use disorder (AUD). The multinational, multi-center trial will assess tolerability, safety, and pharmacokinetics in healthy volunteers and AUD subjects.

The trial will be conducted at leading universities in the US, including Yale and Johns Hopkins, as well as in Israel. The primary endpoint is to determine the tolerable dose and characterize safety and pharmacokinetics, while the secondary endpoint will evaluate preliminary efficacy in reducing drinking patterns and cravings in moderate-to-severe AUD patients.

Clearmind Medicine Inc. (Nasdaq: CMND) has submitted a new patent application to the USPTO for a novel composition combining its MEAI compound with SciSparc's PEA to treat metabolic syndrome and obesity. This application is part of ongoing collaborations with SciSparc (Nasdaq: SPRC) and Prof. Joseph Tam from the Hebrew University.

The obesity treatment market, valued at $15 billion in 2022, is expected to grow at a CAGR of 10.0% from 2023 to 2032. This growth is driven by the increasing prevalence of obesity, with the CDC reporting a 41.9% obesity rate among US adults aged 20 and over.

Clearmind has filed a total of twelve patent applications with the USPTO for various proprietary compositions, including treatments for alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders.

Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech firm, will present significant research at the Psychedelic Medicine – Israel 2024 conference in Tel Aviv from July 28-30. CEO Adi Zullof-Shani, Ph.D., will discuss the potential of 5-Methoxy-2-Aminoindane (MEAI) as a regulator of binge behaviors on July 29. Additionally, researchers Prof. Joseph Tam and Dr. Saja Baraghithy will present a study on MEAI's effects on diet-induced obesity on July 30. Their findings indicate MEAI's promise in reducing obesity and improving metabolic health. The conference aims to advance psychedelic medicine through international collaboration and research dissemination.

Clearmind Medicine, focused on developing psychedelic-derived therapeutics, announced patent approval for its MEAI-based binge behavior regulator in Hong Kong. The newly granted patent enhances Clearmind's intellectual property portfolio, which now includes 28 patents across 18 patent families in key regions like the US, Europe, China, India, and Hong Kong. The company's innovative molecule, MEAI, reduces the desire to consume alcohol and provides a mild euphoria similar to alcohol. This treatment is particularly aimed at managing Alcohol Use Disorder and binge drinking, offering potential benefits to millions who struggle with alcohol moderation.

Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech firm, has secured an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This deal grants Clearmind global rights to develop, manufacture, and commercialize novel psychedelic-derived compounds aimed at treating PTSD and other mental health conditions. The potential PTSD treatment market is estimated to grow from $16.8 billion in 2023 to $27.37 billion by 2033. Current treatments for PTSD, such as SSRIs and SNRIs, often show efficacy and side effects like nausea and insomnia. Clearmind's agreement includes milestone payments, royalties, and IP protection commitments.

Clearmind Medicine (Nasdaq: CMND) announced advancements in its MEAI-based alcohol substitute beverage program, targeting the $13 billion non-alcoholic beverages market. The company completed the last pre-clinical study needed for a novel-food application. This project, led by Nicholas Kadysh, an expert with former roles at Red Bull Canada and Juul Labs Canada, has received patents in the U.S., India, and Europe. According to IWSR, the no/low alcohol market, valued at $13 billion in 2023, is expected to grow at a CAGR of 6% through 2027. Clearmind aims to develop psychedelic-derived therapeutics for under-treated health problems, boasting a portfolio of 18 patent families and 27 granted patents.

Clearmind Medicine Inc. announces progress in its proprietary MEAI-based alcohol substitute beverage program, aiming to introduce a health-focused alternative to traditional alcoholic drinks. The company has completed pre-clinical studies for a novel-food application submission and obtained patents in the U.S., India, and Europe. Led by industry experts, the project aligns with the global trend towards no- and low-alcohol consumption in a market estimated to be over $13 billion by 2023.

Clearmind Medicine Inc. (Nasdaq: CMND) secures global rights to innovative psychedelic compounds for PTSD treatment through an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. The global market for PTSD treatment is projected to reach $27.37 billion by 2033. Clearmind aims to revolutionize mental health care with these novel compounds, offering hope to millions worldwide.